ArticleAlzheimer's research & therapy2018
Cognitive composite score association with Alzheimer's disease plaque and tangle pathology.
Article in Alzheimer's research & therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Data‑driven cognitive composites predict Aβ‑related decline and progression to MCI: the ADOPIC study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Cognitive function in adult NF1 patients without other cognitive disorders: a cross-sectional study.Orphanet journal of rare diseases · 2026Article
- Neurocognitive trajectories in long COVID: Evidence from longitudinal analyses.Brain, behavior, & immunity - health · 2025Article
- Layer-Specific Colocalization of Microglia with Amyloid Plaques in the Middle Temporal Gyrus Predicts Cognitive Decline in Alzheimer's Disease.Aging and disease · 2025Article
- Repeated plasma p-tau217 measurements to monitor clinical progression heterogeneity.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- APOEε4 alters ApoE and Fabp7 in frontal cortex white matter in prodromal Alzheimer's disease.Journal of neuroinflammation · 2025Article
- Comparing Cognitive Tests and Smartphone-Based Assessment in 2 US Community-Based Cohorts.Journal of the American Heart Association · 2024Article
- Could tau-PET imaging contribute to a better understanding of the different patterns of clinical progression in Alzheimer's disease? A 2-year longitudinal study.Alzheimer's research & therapy · 2023Article
- BMP4-SMAD1/5/9-RUNX2 pathway activation inhibits neurogenesis and oligodendrogenesis in Alzheimer's patients' iPSCs in senescence-related conditions.Stem cell reports · 2023Article
- Importance of high-quality evidence regarding the use of Bacopa monnieri in dementia.Frontiers in aging neuroscience · 2023Review
- Combining tau-PET and fMRI meta-analyses for patient-centered prediction of cognitive decline in Alzheimer's disease.Alzheimer's research & therapy · 2022Article
- Transcranial Electromagnetic Treatment Stops Alzheimer's Disease Cognitive Decline over a 2½-Year Period: A Pilot Study.Medicines (Basel, Switzerland) · 2022Article
- Use of Bacopa monnieri in the Treatment of Dementia Due to Alzheimer Disease: Systematic Review of Randomized Controlled Trials.Interactive journal of medical research · 2022Review
- Latest Trends in Outcome Measures in Dementia and Mild Cognitive Impairment Trials.Brain sciences · 2022Review
- Cross-Cultural Comparisons of Subjective Cognitive Complaints in a Diverse Primary Care Population.Journal of Alzheimer's disease : JAD · 2021Article
- Brain lipid peroxidation and alzheimer disease: Synergy between the Butterfield and Mattson laboratories.Ageing research reviews · 2020Review
- Regional binding of tau and amyloid PET tracers in Down syndrome autopsy brain tissue.Molecular neurodegeneration · 2020Article
- Braak Stage, Cerebral Amyloid Angiopathy, and Cognitive Decline in Early Alzheimer's Disease.Journal of Alzheimer's disease : JAD · 2020Article
- Associations between NIH Toolbox Cognition Battery andAlzheimer's & dementia (Amsterdam, Netherlands) · 2020Article
- Analyzing large Alzheimer's disease cognitive datasets: Considerations and challenges.Alzheimer's & dementia (Amsterdam, Netherlands) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundCognitive composite scores are used as the primary outcome measures for Alzheimer's disease (AD) prevention trials; however, the extent to which these composite measures correlate with AD pathology has not been fully investigated. Since many on-going AD prevention studies are testing therapies that target either amyloid or tau, we sought to establish an association between a cognitive composite score and the underlying pathology of AD.
methodsData from 192 older deceased and autopsied persons from the Rush Religious Order Study were used in this study. All participants were classified at their initial evaluations with a clinical diagnosis of no cognitive impairment (NCI). Of these individuals, 105 remained NCI at the time of their death while the remaining 87 progressed to mild cognitive impairment (MCI) or AD. A cognitive composite score composed of eight cognitive tests was used as the outcome measure. Individuals were classified into groups based on Consortium to Establish a Registry for Alzheimer's Disease (CERAD) neuropathological diagnosis and Braak stage.
resultsThe rate of annualized composite score decline was significantly greater for the high CERAD (p < 0.001, d = 0.56) and Braak (p < 0.001, d = 0.55) groups compared with the low CERAD and Braak groups, respectively. Mixed-model repeated measure (MMRM) analyses revealed a significantly greater difference in composite score change from baseline for the high CERAD group relative to the low CERAD group after 5 years (Δ = -2.74, 95% confidence interval (CI) -5.01 to -0.47; p = 0.02). A similar analysis between low and high Braak stage groups found no significant difference in change from baseline (Δ = -0.69, 95% CI -3.03 to 1.66; p = 0.56).
conclusionsThese data provide evidence that decreased cognitive composite scores were significantly associated with increased AD pathology and provide support for the use of cognitive composite scores in AD prevention trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.